Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2025 - 2033
Description
Lung Cancer Diagnostics Market Summary
The global lung cancer diagnostics market size was estimated at USD 12.37 billion in 2024 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The market encompasses diagnostic technologies designed to facilitate the early detection and accurate classification of lung cancer, which remains one of the leading causes of cancer-related mortality worldwide.
A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.
Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.
Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.
Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.
Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.
Global Lung Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the lung cancer diagnostics market report based on type, test, end use, and region:
The global lung cancer diagnostics market size was estimated at USD 12.37 billion in 2024 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The market encompasses diagnostic technologies designed to facilitate the early detection and accurate classification of lung cancer, which remains one of the leading causes of cancer-related mortality worldwide.
A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.
Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.
Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.
Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.
Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.
Global Lung Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the lung cancer diagnostics market report based on type, test, end use, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Non-small cell lung cancer
- Small cell lung cancer
- Test Outlook (Revenue, USD Million, 2021 - 2033)
- CA test
- HER2 test
- ALK test
- Angiogenesis Inhibitors
- EGFR Mutation test
- KRAS Mutation test
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Laboratories
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation
- 1.1.1. Market Definitions
- 1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. Gvr’s Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. List of Primary Sources
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers
- 3.4.1. Rising Lung Cancer Incidence
- 3.4.2. Growing Adoption of Biomarker and Molecular Testing
- 3.4.3. Technological Advancements in Imaging and Liquid Biopsy
- 3.5. Market Restraint Analysis
- 3.5.1. High Cost of Advanced Diagnostic Tests
- 3.5.2. Limited Infrastructure in Emerging Economies
- 3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter’s Five Forces Analysis
- 3.6.3. COVID-19 Impact Analysis
- Chapter 4. Type Business Analysis
- 4.1. Lung Cancer Diagnostics Market: Type Movement Analysis
- 4.2. Non-small Cell Lung Cancer
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Small Cell Lung Cancer
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Test Business Analysis
- 5.1. Lung Cancer Diagnostics Market: Test Movement Analysis
- 5.2. CA Test
- 5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. HER2 Test
- 5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. ALK Test
- 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Angiogenesis Inhibitors
- 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. EGFR Mutation test
- 5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. KRAS Mutation test
- 5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. End Use Business Analysis
- 6.1. Lung Cancer Diagnostics Market: End Use Movement Analysis
- 6.2. Hospitals
- 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Laboratories
- 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Others
- 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Regional Business Analysis
- 7.1. Lung Cancer Diagnostics Market Share By Region, 2023 & 2033
- 7.2. North America
- 7.2.1. North America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Target Disease Prevalence
- 7.2.2.3. Competitive Scenario
- 7.2.2.4. Regulatory Framework
- 7.2.2.5. Reimbursement Scenario
- 7.2.2.6. U.S. Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Target Disease Prevalence
- 7.2.3.3. Competitive Scenario
- 7.2.3.4. Regulatory Framework
- 7.2.3.5. Reimbursement Scenario
- 7.2.3.6. Canada Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Target Disease Prevalence
- 7.2.4.3. Competitive Scenario
- 7.2.4.4. Regulatory Framework
- 7.2.4.5. Reimbursement Scenario
- 7.2.4.6. Mexico Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. Reimbursement Scenario
- 7.3.2.6. Germany Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Reimbursement Scenario
- 7.3.3.6. UK Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Reimbursement Scenario
- 7.3.4.6. France Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Target Disease Prevalence
- 7.3.5.3. Competitive Scenario
- 7.3.5.4. Regulatory Framework
- 7.3.5.5. Reimbursement Scenario
- 7.3.5.6. Italy Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Target Disease Prevalence
- 7.3.6.3. Competitive Scenario
- 7.3.6.4. Regulatory Framework
- 7.3.6.5. Reimbursement Scenario
- 7.3.6.6. Spain Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Target Disease Prevalence
- 7.3.7.3. Competitive Scenario
- 7.3.7.4. Regulatory Framework
- 7.3.7.5. Reimbursement Scenario
- 7.3.7.6. Denmark Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Target Disease Prevalence
- 7.3.8.3. Competitive Scenario
- 7.3.8.4. Regulatory Framework
- 7.3.8.5. Reimbursement Scenario
- 7.3.8.6. Sweden Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Target Disease Prevalence
- 7.3.9.3. Competitive Scenario
- 7.3.9.4. Regulatory Framework
- 7.3.9.5. Reimbursement Scenario
- 7.3.9.6. Norway Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. Reimbursement Scenario
- 7.4.2.6. Japan Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Reimbursement Scenario
- 7.4.3.6. China Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. Reimbursement Scenario
- 7.4.4.6. India Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Reimbursement Scenario
- 7.4.5.6. South Korea Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Reimbursement Scenario
- 7.4.6.6. Australia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Reimbursement Scenario
- 7.4.7.6. Thailand Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Reimbursement Scenario
- 7.5.2.6. Brazil Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. Reimbursement Scenario
- 7.5.3.6. Argentina Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Reimbursement Scenario
- 7.6.2.6. South Africa Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Reimbursement Scenario
- 7.6.3.6. Saudi Arabia Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Competitive Scenario
- 7.6.4.4. Regulatory Framework
- 7.6.4.5. Reimbursement Scenario
- 7.6.4.6. UAE Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Competitive Scenario
- 7.6.5.4. Regulatory Framework
- 7.6.5.5. Reimbursement Scenario
- 7.6.5.6. Kuwait Lung Cancer Diagnostics market, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant’s overview
- 8.2. Financial performance
- 8.3. Participant categorization
- 8.3.1. Market Leaders
- 8.3.2. Lung Cancer Diagnostics Market Share Analysis, 2023
- 8.3.3. Company Profiles
- 8.3.3.1. F. Hoffmann-La Roche Ltd
- 8.3.3.1.1. Company Overview
- 8.3.3.1.2. Financial Performance
- 8.3.3.1.3. Product Benchmarking
- 8.3.3.1.4. Strategic Initiatives
- 8.3.3.2. Thermo Fisher Scientific
- 8.3.3.2.1. Company Overview
- 8.3.3.2.2. Financial Performance
- 8.3.3.2.3. Product Benchmarking
- 8.3.3.2.4. Strategic Initiatives
- 8.3.3.3. Illumina Inc.
- 8.3.3.3.1. Company Overview
- 8.3.3.3.2. Financial Performance
- 8.3.3.3.3. Product Benchmarking
- 8.3.3.3.4. Strategic Initiatives
- 8.3.3.4. Agilent Technologies
- 8.3.3.4.1. Company Overview
- 8.3.3.4.2. Financial Performance
- 8.3.3.4.3. Product Benchmarking
- 8.3.3.4.4. Strategic Initiatives
- 8.3.3.5. QIAGEN
- 8.3.3.5.1. Company Overview
- 8.3.3.5.2. Financial Performance
- 8.3.3.5.3. Product Benchmarking
- 8.3.3.5.4. Strategic Initiatives
- 8.3.3.6. Abbott
- 8.3.3.6.1. Company Overview
- 8.3.3.6.2. Financial Performance
- 8.3.3.6.3. Product Benchmarking
- 8.3.3.6.4. Strategic Initiatives
- 8.3.3.7. Bio-Rad
- 8.3.3.7.1. Company Overview
- 8.3.3.7.2. Financial Performance
- 8.3.3.7.3. Product Benchmarking
- 8.3.3.7.4. Strategic Initiatives
- 8.3.3.8. Neogenomics Laboratories
- 8.3.3.8.1. Company Overview
- 8.3.3.8.2. Financial Performance
- 8.3.3.8.3. Product Benchmarking
- 8.3.3.8.4. Strategic Initiatives
- 8.3.3.9. bioMérieux
- 8.3.3.9.1. Company Overview
- 8.3.3.9.2. Financial Performance
- 8.3.3.9.3. Product Benchmarking
- 8.3.3.9.4. Strategic Initiatives
- 8.3.3.10. Myriad Genetics, Inc.
- 8.3.3.10.1. Company Overview
- 8.3.3.10.2. Financial Performance
- 8.3.3.10.3. Product Benchmarking
- 8.3.3.10.4. Strategic Initiatives
- 8.3.4. Strategy Mapping
- 8.3.4.1. Expansion
- 8.3.4.2. Acquisition
- 8.3.4.3. Collaborations
- 8.3.4.4. Disease Type/Drug Class Launch
- 8.3.4.5. Partnerships
- 8.3.4.6. Others
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
